Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249960 | 0.88 | MMP13 (0.47) | MAPTMMP13MMP1MMP2MMP9 | |
| SCHEMBL3255095 | 0.87 | MMP13 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14569172 | 0.87 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6205985 | 0.81 | CYP2D6 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL959465 | 0.80 | APP (0.61) | NPC1SMN1; SMN2ALDH1A1MAPTMMP13 | |
| SCHEMBL7058945 | 0.79 | MMP13 (0.35) | MMP13CA12CA1CA2CA9 | |
| SCHEMBL6206170 | 0.78 | L3MBTL1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7337943 | 0.78 | CA2 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6955062 | 0.78 | CA2 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7056446 | 0.78 | CA12 (0.41) | NPC1SMN1; SMN2ALDH1A1MAPTMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373262-B1 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | NOVARTIS AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | FUJIMOTO ROGER AKI (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1373262-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072577-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS. | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | NPC1 2131/4885RAB9A 1513/4885SMN1; SMN2 2598/4885 |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | MMP1, MMP9, MMP13 | NPC1 1567/4885RAB9A 1715/4885SMN1; SMN2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.